Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...
Streetwise Reports | September 13, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Will the Fed Going Nuclear Help the Economy and Gold?

On Monday, the Fed introduced QE-infinity. What does it imply for the US economy and the gold market? Fed Drops Bazooka… and Goes Nuclear Instead! On Monday, the Fed pulled out an even larger bazooka than it did previously. Or, forget about the bazooka. The US c...
Arkadiusz Sieron | March 26, 2020 |

Q2 Earnings Soar for AI-Assisted Advertising Technology Firm

This small-cap firm saw rapid growth and reported a record second quarter. Adcore Inc. (ADCO:TSX.V) , the developer of machine-learning powered advertising technologies, reported record second quarter financials, including an increase in revenue growth of 53% year o...
Streetwise Reports | August 30, 2019 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

Natural Gas Stocks Ride Upcoming Wave of Oil Well Closures

2019 was such a rough year for natural gas that by the time February 2020 rolled by, hedge funds had built up the largest net short position on record for the sector. Those investors have suddenly developed a strong appetite for natural gas stocks and bonds on the expecta...
Streetwise Reports | May 15, 2020 |

Precious Metals Streamer's Q4/18 EPS a Beat, 2019 Guidance with 'Rosy Upside'

A BMO Capital Markets report presented both sets of figures. In a March 20 research note, BMO Capital Markets analyst Andrew Kaip reported that Wheaton Precious Metals Corp. (WPM:TSX; WPM:NYSE) beat earnings per share (EPS) estimates in Q4/18 and, looking forward, the...
Streetwise Reports | March 26, 2019 |

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. In an April 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed the reasons why Galmed Pharmaceuticals Ltd. (GLMD:NASDAQ) is "high on the...
Streetwise Reports | April 18, 2019 |

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. In a May 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that for Nabriva Therapeutics Plc (NBRV:NASDAQ) , "all eyes [are] on [its] Au...
Streetwise Reports | May 16, 2019 |
1 2 3 4 5 6 7 8 9 10 ...